key: cord-0833655-fw5oz3jk
authors: Grant, Stephen N.; Lester, Henry A.
title: Regulation of epithelial sodium channel activity by SARS-CoV-1 and SARS-CoV-2 proteins
date: 2021-06-29
journal: Biophys J
DOI: 10.1016/j.bpj.2021.06.005
sha: cc1c4619717b089dc7d28dd67d12d28cf8d31f19
doc_id: 833655
cord_uid: fw5oz3jk

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19), encodes several proteins whose roles are poorly understood. We tested their ability either to directly form plasma membrane ion channels or to change functions of two mammalian plasma membrane ion channels, the epithelial sodium channel (ENaC) and the α3β4 nicotinic acetylcholine receptor (nAChR). In mRNA-injected Xenopus oocytes, none of nine SARS-CoV-2 proteins or two SARS-CoV-1 proteins produced conductances, nor did co-injection of several combinations. Immunoblots for ORF8, spike (S), and envelope (E) proteins revealed that the proteins are expressed at appropriate molecular weights. In experiments on co-expression with ENaC, three tested SARs proteins (SARS-CoV-1 E, SARS-CoV-2 E, and SARS-CoV-2 S) markedly decrease ENaC currents. SARS-CoV-1 S protein decreases ENaC currents modestly. Co-expressing the E proteins, but not the S proteins, with α3β4 nAChRs significantly reduces acetylcholine-induced currents. ENaC inhibition does not occur if the SARS-CoV protein mRNAs are injected 24 h after the ENaC mRNAs, suggesting that SARS-CoV proteins affect early step(s) in functional expression of channel proteins. Consistent with the hypothesis that the SARS-CoV-2 S protein-induced ENaC inhibition involves competition for available protease, mutating the furin cleavage site in SARS-CoV-2 S protein partially relieves inhibition of ENaC currents. Extending previous suggestions that SARS proteins affect ENaC currents via protein kinase C (PKC) activation, PKC activation via phorbol 12-myristate 13-acetate (PMA) decreases ENaC and α3β4 activity. PMA application reduced membrane capacitance ∼ 5%, presumably via increased endocytosis; but this decrease is much smaller than the SARS proteins’ effects on conductances. Also, incubating oocytes in Gö-6976, a PKCα and PKCβ inhibitor, did not alter E or S protein-induced channel inhibition. We conclude that SARS-CoV-1 and SARS-CoV-2 proteins alter the function of human plasma membrane channels, via incompletely understood mechanisms. These interactions may play a role in COVID-19 pathophysiology.

COVID-19 has caused a massive global public health crisis. As of 19 April 2021, over 140 million people have been infected and over three million lives have been lost to COVID-19, according to the Johns Hopkins Coronavirus Resource Center. The pandemic has spurred drastic changes throughout the world in every part of life. Understanding this virus gives the global community its best chance to return to relatively standard practices. However, much like the pandemic it elicited, SARS-CoV-2 is an unprecedented virus that requires study from various approaches.

We sought to contribute to COVID-19 research by systematically studying membrane-relevant SARS-CoV-2 proteins, both by themselves and in various combinations with host proteins, and comparing homologous proteins from SARS-CoV-1 and SARS-CoV-2. Plasma membrane viroporins are important for many viruses (1) (2) (3) (4) (5) , and we tested for their presence in SARS-CoV-2 by expressing SARS-CoV-1 and SARS-CoV-2 proteins in Xenopus oocytes.

It is important to understand how the various proteins encoded by SARS-CoV-2 interact with endogenous human proteins (2, 6, 7) . SARS-CoV-2 must interact with host proteins to replicate(8). These interactions begin when the SARS-CoV-2 S protein binds to the human angiotensin-converting enzyme 2 (ACE2) protein; this interaction leads to viral entry (9-11). Many subsequent interactions have been studied between SARS-CoV-2 and human proteins. Studies using mass spectrometry and in silico methods identified many protein-protein interactions between SARS-CoV-2 and humans (7, 12) . Additionally, researchers have looked to work done on SARS-CoV-1, the related beta-coronavirus responsible for the SARS epidemic in 2002 and 2003 (13) .

We are also interested in how the E and S proteins from SARS-CoV-2 affect ENaC function. Ji et al. used electrophysiology to suggest that both SARS-CoV-1 E and S proteins markedly decreased ENaC activity in Xenopus laevis oocytes (14) . After pharmacological experiments to probe the cause of this inhibition, Ji et al. suggested that the E and S protein decreased ENaC protein levels via a protein kinase C (PKC)-dependent mechanism (14) . ENaC helps regulate fluid levels in the lung, and if this function is inhibited, pulmonary edema can develop (15) . Pulmonary edema has been observed in COVID-19 patients, so inhibition of ENaC via E and S protein expression may have been conserved in SARS-CoV-2 (16, 17) . Other ion channels may be affected by SARS-CoV-2 proteins, so we tested the generality of our results by studying how the SARS-CoV-1 and SARS-CoV-2 proteins affect α3β4 nAChR activity. Finally, we begin mechanistic work to explain how the SARS-CoV-1 and SARS-CoV-2 proteins affect ENaC and α3β4 nAChR currents.

Human ENaC subunit cDNAs h-alpha-ENaC, h-beta-ENaC, and h-gamma-ENaC Myc were gifts from Christie Thomas (18) 

pLVX-EF1alpha-SARS-CoV-2-M-2xStrep-IRES-Puro were gifts from Nevan Krogan (7) . pDONR223 SARS-CoV-2 NSP6 and pDONR207 SARS-CoV-2 NSP3 were gifts from Fritz Roth. pUC57-2019-nCoV-S plasmid was purchased from MolecularCloud. pcDNA3.1-SARS-Spike was a gift from Fang Li (19) . The SARS-CoV-2 E protein plasmid was constructed and packaged by VectorBuilder. The vector ID, VB200324-4348fzb, provides information about the vector on vectorbuilder.com. SARS-CoV-1 E protein was produced by introducing point mutations in the SARS-CoV-2 E protein plasmid. All SARS-CoV-1 and SARS-CoV-2 proteins were cloned into the pGEMHE vector for optimal Xenopus oocyte expression. The mouse α3 and β4 nicotinic acetylcholine receptor mRNA have been described previously (20) . mRNA was produced using the mMessage mMachine T7 transcription kit (Invitrogen) and purified with the RNeasy Mini Kit (Qiagen).

Xenopus laevis stage V and VI oocytes were harvested via standard protocols (21) . For each ENaC subunit, 12 ng of mRNA was injected into oocytes. For mouse α3β4 nAChR expression, 10 ng of mRNA for each subunit were injected into each oocyte. For the SARS-CoV-1 or SARS-CoV-2 proteins, 20 ng of mRNA were injected into oocytes along with the ENaC or α3β4 nAChR mRNA. For oocytes injected with a single SARS-CoV-2 protein mRNA, each oocyte received 20 ng of mRNA. For oocytes injected with nine SARS-CoV-2 and two SARS-CoV-1 protein mRNA, 3 ng of each were injected into each oocyte. The final mRNA injection took place 24 hours before electrophysiological recording or 48 hours before lysis for immunoblotting.

Immunoblotting 48 hours post-injection, oocyte lysates were prepared by lysing oocytes osmotically in a 20 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), pH 7.3 solution (20 µL per oocyte)(22). Lysates were centrifuged for 5 minutes at 10,000 rpm. The supernatant was used to probe for E protein. The pellets were resuspended in 50 mM Tris, 150 mM NaCl, 1% NP-40, pH 7.3 buffer and these solutions were used to probe for ORF8 and S protein. 12% Mini-PROTEAN® TGX™ Precast Protein Gels (Bio-Rad) were used for electrophoresis and wettransferred onto an immun-Blot® LF PVDF membrane (Bio-Rad). E protein was probed using rabbit antiserum that responds to the C-terminus of SARS-CoV-1 E protein at 1:1000 concentration. The antiserum was a gift from Carolyn Machamer (23) . The ORF8 was probed using a primary antibody at 1:500 concentration (GeneTex, Cat#: GTX135591). S protein was probed using a primary antibody at 1:500 concentration (Invitrogen, Cat#: PA581795). The primary antibodies were visualized using IRDye® 800 CW donkey anti-rabbit antibody (Li-Cor, Cat#: 926-32213) at 1:1000 concentration.

Oocyte recordings were performed in two-electrode voltage-clamp mode using the OpusXpress 6000A instrument (Axon Instruments). Oocyte equilibration and washes were performed with ND96 [96 mM NaCl, 2 mM KCl, 1.8 mM CaCl2, 1 mM MgCl2, and 5 mM HEPES (pH 7.4)] or High K + buffer [2 mM NaCl, 96 mM KCl, 1.8 mM CaCl2, 1 mM MgCl2, and 5 mM HEPES (pH 7.4)]. Microelectrodes were fabricated from borosilicate glass (BF150-117-15, Sutter Instrument Company, Novato, CA) using a one-stage horizontal pull (P-87, Sutter Instrument Co., Novato, CA) and filled with 3 M KCl. Pipette resistances ranged from 0.3 to 3.0 MΩ. The initial holding potential was +10 mV for ENaC expressing oocytes or -60 mV for α3β4 expressing oocytes. For ENaC expressing oocytes, voltages were sampled from -120 mV to +70 mV at 10 mV intervals and the currents through the oocyte membrane were recorded. For α3β4 expressing oocytes, the potential was held at -60 mV throughout the experiment and the currents were measured during 100 µM acetylcholine (ACh) application. Data were sampled at 50 Hz. Traces were processed in Clampfit 11.1. In ENaC expressing oocytes, amiloride-sensitive currents were calculated by subtracting currents measured in the presence of 10 µM amiloride (an ENaC inhibitor) from the average currents measured in ND96 taken before amiloride treatment and after amiloride washout. For PMA experiments, oocyte currents were measured before and after 15 minute incubation in the vehicle or 10 µM PMA. For Gö-6976 experiments, the oocytes were incubated in 1 µM Gö-6976 right after injection until electrophysiology experiments were performed.

Analysis and curve fitting was performed using Prism (GraphPad Software, La Jolla, CA). For the ENaC experiments in Figs. 3, 5, 6, 7, and 8, we fitted a second-order polynomial to each current-voltage dataset (> 10 oocytes, except where noted), to account for the nonlinear ENaC conductance. For control currents (for instance, co-injection with ORF8), the reversal potential (V 0 ) varied < 5 mV within each experiment; however, the much smaller currents resulting from co-injection of other SARS-Cov-1 and SARS-CoV-2 proteins vitiated a meaningful estimate of V 0 . The data plots show the 95% confidence limits of these fitting functions at each voltage between -120 mV and +70 mV. "Significant differences" between current-voltage relations in a particular voltage range mean that the 95% confidence limits do not overlap in that voltage range. This presentation has the physiological and pathophysiological relevance (a) that ENaC is expressed primarily in epithelial cells-a likely site of SARS-Cov-2 infection and proliferation(24-26)--and (b) where possible, we extend the analysis to the > -60 mV resting potentials typical of epithelial cells.

Membrane capacitance was measured on oocytes for each voltage jump. The capacitive charge ∆Q was calculated by temporally integrating the transient capacitive current (∆Q = ∫∆I) during the 20 ms following the command voltage jump. Figures 3A and 3C show how relatively large conductive currents challenge the voltage-clamp circuitry, the current amplifier's compliance, and the linearity of the current electrode so that ∆Q becomes distorted by the presence of a large J o u r n a l P r e -p r o o f

conductance. An example of the resulting artifact is our lab's erroneous overestimate of the decreases in oocyte capacitance that accompany large decreases in K + currents (27) . To minimize such artifacts in the present experiments, we measured capacitance during the blockade of most ENaC currents by amiloride (10 mM). We also subtracted remaining time-independent conductive currents by extrapolating such currents back to the time of the jump in the command voltage. We verified that the capacitive transient ∆Q showed a linear dependence on the voltage jump ∆V, allowing us to measure C = ∆V/∆Q.

In analyses of data that emphasized currents at a single potential, an unpaired t-test was used to determine statistical significance between results with ORF8 coinjection vs each other coinjection (Fig. 4) . A p-value of 0.05 or less was considered to be statistically significant. Results

Many viruses rely on the function of viroporins, including viruses in the coronavirus family (2 , 4, 6, 23, 28) . The ORF3a and E protein are postulated to be viroporins (29). Furthermore, there are viral protein-protein interactions such that the individual protein do not create a pore, but together they do so (30) . Here we find that the injection of SARS-CoV-1 S and E and SARS-CoV-2 Nsp2, Nsp3, Nsp4, Nsp6, ORF3a, ORF8, M, E, and S protein mRNA, all simultaneously or individually, into Xenopus oocytes does not produce conductances in the plasma membrane ( Fig. 1) .

While most properly transcribed mRNA is translated into proteins when injected into oocytes, there are exceptions. Here, we made immunoblots to determine whether a subset of these SARS proteins are translated in oocytes. We specifically studied the S, E, and SARS-CoV-2 ORF8 proteins. Each SARS protein was only observed in oocytes injected with their respective mRNA (Fig. 2) . These results suggest that S, E, and SARS-CoV-2 ORF8 proteins are expressed in the oocytes following mRNA injection; inadequate protein translation or protein degradation does not underlie the lack of plasma membrane conductances.

Protein-protein interactions between the virus and host are crucial for viral entry, replication, maturation, transport, and secretion. Ji et al. investigated the SARS-CoV-1 E and S protein interactions with ENaC (14) . Here, we repeated these experiments and included the SARS-CoV-2 proteins (Fig. 3) . We use SARS-CoV-2 ORF8 as a negative control plasmid since ORF8 does not produce viroporins in the plasma membrane and is not expected to interact with ENaC (29). Compared to oocytes injected with ORF8, oocytes injected with SARS-CoV-1 E, SARS-CoV-2 E, and SARS-CoV-2 S protein decrease ENaC currents, with the E proteins having a greater effect than SARS-CoV-2 S protein. Furthermore, we find that SARS-CoV-2 E protein inhibits ENaC more than SARS-CoV-1 E protein. Although Ji et al. report that SARS-CoV-1 S protein also decreases ENaC current, we find that this is true compared to oocytes injected only with ENaC, the control Ji et al. used. However, when the control is oocytes co-injected with ORF8, there is no significant difference between oocytes co-injected with SARS-CoV-1 S or the control mRNA. Altogether, we find that the E and S protein from SARS-CoV-2 have a greater inhibitory effect on ENaC than their SARS-CoV-1 counterparts.

The SARS-CoV-1 and -2 E proteins differ at two sequence regions, positions 55-56 and 69-70. We constructed two chimera-like E proteins in which either the 55-56 or 69-70 sequences differ, but not both. Proteins with the SARS-CoV-1 E protein residues at 69-70 are one amino acid longer than proteins with the SARS-CoV-2 E protein residues at 69-70 because this sequence is Glu-Gly in SARS-CoV-1 and Arg-(∆) in SARS-CoV-2. Like both unmutated E proteins, both of these chimera-like proteins markedly decreased ENaC current.

Next, we were interested in the SARS proteins' general effect on ion channels. We studied the α3β4 nAChR as it is readily expressed in Xenopus oocytes and plays a role in several respiratory diseases (31) . Once again, we find that α3β4 currents are significantly reduced when oocytes are co-injected with either E protein (Fig. 4) . However, in contrast to our ENaC experiments, SARS-CoV-2 S protein does not significantly reduce α3β4 currents.

The individual ENaC subunits must be translated, folded, assembled into mature channels, and trafficked to the plasma membrane. ENaC currents are observed 24 hours after mRNA injection, suggesting that these steps occur within that time. To understand whether the SARS-CoV proteins affect ENaC during these steps, we injected ENaC mRNA, and waited 24 hours before injecting the SARS-CoV mRNA. We find that if the SARS-CoV mRNA is injected 24 hours after the ENaC mRNA, there is no ENaC inhibition (Fig. 5) .

We interpret the experiment of Figure 5 as follows. On the one hand, delaying ORF8 injection by 24 h significantly increases ENaC conductance by 2 -3 fold, at V < -30 mV and V > +40 mV. This effect may indicate that ORF8 inhibits ENaC expression or function modestly during the first 24 h after co-injection. On the other hand, delaying the 2-S, 1-E, or 2-E mRNA injection by 24 h produces more dramatic increases. Quantitative comparisons are vitiated by the very small currents produced by co-injection; but the increase is > 10-fold. Therefore, we conclude that the severe block of ENaC by SARS-CoV-1 E, SARS-CoV-2 S, or SARS-CoV-2 E proteins all occur at early steps in the functional expression of channel proteins. The relatively modest block by SARS-CoV-1 S protein presents an intermediate case. Delaying SAR-CoV-1 S co-injection by 24 h produces a ~ 4-fold increase in ENaC conductance when measured at all voltages outside the -20 mV to + 20 mV range.

ENaC function is dependent on a furin cleavage event, while α3β4 does not depend on furin cleavage (32) . The ability of SARS-CoV-2 S protein to inhibit ENaC, but not α3β4, could be explained by the furin cleavage site in SARS-CoV-2 S protein that may compete for available furin. Indeed, several others have proposed this mechanism for possible ENaC inhibition via SARS-CoV-2 S protein expression (33) (34) (35) . We mutated the 682 RRAR 685 motif to 682 AAAR 685 to destroy the furin cleavage site. In oocytes expressing ENaC, there was greater current when we expressed the SARS-CoV-2 S [ 682 AAAR 685 ] mutant instead of the wild-type SARS-CoV-2 S protein (Fig. 6) . However, the currents were not completely restored, suggesting that other factors influence ENaC inhibition by SARS-CoV-2 S protein.

PKC helps regulate many cellular functions, including net endocytosis(36). Ji et al. suggested that PKC activation is the cause for decreased ENaC currents due to SARS-CoV-1 S or E protein expression. They hypothesized that as endocytosis occurs, the number of ENaC channels on the plasma membrane decrease, and the total ENaC current decreases pari passu. Here, we verify that PKC activation decreases ENaC and α3β4 currents after 15 minute treatment in 10 µM phorbol 12-myristate 13-acetate (PMA), a PKC activator (37) . We find that compared to vehicle, currents are significantly lower after PMA treatment, consistent with Ji et al.'s hypothesis that PKC activation decreases plasma membrane currents (Fig. 7) . Additionally, based on our capacitance measurements, net endocytosis increased (membrane area decreased ~5%) following PMA treatment (Fig. S1 in the Supporting Material).

We tried to inhibit PKC activation with Gö-6976, a known PKC inhibitor (38) . We hypothesized that if we can prevent PKC activation with Gö-6976, then the effects of SARS-CoV-1 E, SARS-CoV-2 S, and SARS-CoV-2 E will be abolished. However, after incubating oocytes in 1 µM Gö-6976 following mRNA injection, we found no differences between Gö-6976 treated and vehicletreated cells (Fig. 8) . Once again, this is somewhat consistent with Ji et al.'s data in that Gö-6976 treatment did not completely recover ENaC currents, although our data suggest a much less impressive improvement with Gö-6976 treatment. Nonetheless, both Ji et al. and we suggest that although PKC activation can decrease ENaC currents, the SARS proteins appear to be utilizing other mechanisms as well.

COVID-19 has wreaked havoc on the world in unprecedented ways. We show that the SARS-CoV-1 and SARS-CoV-2 proteins, expressed either singly or in combination, do not produce conductance at the plasma membrane (Fig. 1) . This contrasts with reports suggesting that SARS-CoV-1 and SARS-CoV-2 may produce viroporins on the plasma membrane (39) (40) (41) . We verify that proteins are being translated by detecting E, S, and ORF8 proteins via immunoblots (Fig. 2) and by observing inhibition of other channels. While these results do not prove the absence of ion channels in other intracellular regions, the plasma membrane's lack of ion channels casts doubt on some therapeutic strategies.

Caveats include that a Xenopus oocytes differ markedly from human epithelial cells, so further work must be done on other model systems to produce a more comprehensive understanding of SARS-CoV-2 proteins' roles in COVID-19. Also, the intracellular life cycle of a coronavirus involves several steps in organelles; if the SAR-CoV proteins produce channels in organelles, J o u r n a l P r e -p r o o f these might not traffic to the plasma membrane and might therefore escape detection in our experiments.

As in many viral diseases, viral protein-host protein interactions underlie the pathophysiology of COVID-19. Therefore, we have studied interactions that include the effects of E or S protein expression on ENaC or α3β4 activity. In SARS-CoV-1, Ji et al. found that E and S protein expression decreased ENaC activity (14) . Our observations suggest that the inhibitory properties are greater for the SARS-CoV-2 E protein and S protein (Fig. 3) . We found that in α3β4expressing oocytes, both E proteins decreased α3β4 currents (Fig. 4) . For S protein, Ji et al. found that SARS-CoV-1 S protein decreased ENaC activity (14) . In contrast, our results suggest that SARS-CoV-2 S protein, but not SARS-CoV-1 S protein, has this effect. This difference is likely due to a difference in our control experiments. On the one hand, Ji et al. compared their currents to samples only injected with ENaC; on the other hand, we compared our results to samples co-injected with ORF8, a protein that is not expected to interact with ENaC. Therefore, we hypothesize that the decreased ENaC currents that we observe for SARS-CoV-1 S protein (that do not significantly differ from samples injected with ORF8) are due to occlusion of translational or trafficking pathways (42) instead of a selective effect from the translated proteins. However, oocytes co-injected with SARS-CoV-2 S protein did have significantly lower ENaC currents compared to our controls. We show that the inhibitions do not occur if the SARS-CoV protein mRNAs are injected 24 h after ENaC mRNAs, suggesting that SARS-CoV proteins affect early step(s) in the functional expression of channel proteins (Fig. 5) .

Previous studies show that some viral fusion proteins are activated by proteolysis (43) . The increased inhibition with SARS-CoV-2 S protein is consistent with the appearance of a furin cleavage site (44) . This site is identical to the furin cleavage site in the ENaC-α subunit, so SARS-CoV-2 S protein may be competing for available furin, thereby decreasing the proteolytic activation of ENaC-α and thus decreasing ENaC activity (18, 35, 45) . SARS-CoV-2 S protein competing for furin would also explain how α3β4 currents do not change with SARS-CoV-2 S protein expression: α3β4 does not depend on furin cleavage for activity. Our experiments with the SARS-CoV-2 S [ 682 AAAR 685 ] mutant support this hypothesis, although it does not completely explain SARS-CoV-2-induced ENaC inhibition as uninhibited ENaC currents were not observed. (Fig. 6) .

We hypothesized, similarly to Ji et al., that PKC activation may partly underlie the decreased currents (14) . When PKC is activated, net endocytosis increases (36) . Decreasing the number of channels on the membrane via endocytosis is expected to decrease currents. When we examined this relationship quantitatively in oocytes treated with PMA, we observed only a modest (~5%) decrease in membrane area (as a decrease in capacitance) along with a much larger decrease in membrane currents through ENaC and α3β4 ( Fig. 7 and Fig. S1) . Furthermore, when we blocked PKC activation with Gö-6976 treatment, we did not block the inhibitory effects of SARS-CoV-1 E, SARS-CoV-2 E, or SARS-CoV-2 S protein (Fig. 8) . While these SARS proteins may be activating PKC, there appear to be other mechanisms that inhibit ENaC activity as well.

Both chimera-like E protein constructs suppressed ENaC currents like the parent proteins. Although we could not directly probe events in the Golgi (where the E protein is expected to J o u r n a l P r e -p r o o f localize (46) ), this result suggests that combining the two regions conferred no selective advantage to SARS-CoV-2, at least as measured by our assay of ENaC suppression. Among the presently known SARS-CoV-2 variant lineages, we have noted no mutations at the 55-56 and 69-70 positions. Several members of the B.1.351 lineage have a P71L mutation; this position is near the 69-70 sequence and immediately upstream from a candidate PDZ domain binding motif at the C-terminus.

Unfortunately, COVID-19 will not be the last virus to cross over into humans and strain public health resources. While the COVID-19 vaccine will greatly help the world recover from this pandemic, basic research into SARS-CoV-2 will improve our response when the next viral infection emerges.

Because SARS and COVID-19 are different diseases, one expects to note differences between the proteins from SARS-CoV-1 and SARS-CoV-2. Here, we show that the E and S proteins inhibit ENaC and are more potent at inhibiting ENaC than their SARS-CoV-1 counterparts. ENaC participates in lung fluid homeostasis, so an improperly functioning ENaC may result in pulmonary edema (14, 15) . If ENaC is inhibited more in COVID-19 than in SARS, this may help us predict the course of future viral diseases. Indeed, if pulmonary edema is more prominent in COVID-19 patients than SARS patients, the different S and E proteins may be responsible. Additionally, the SARS-CoV-2 variants are troubling. Most researchers emphasize that any differential virulence or lethality of variant S proteins may arise via differential interactions with antibodies-induced either by host infection or by vaccines. The present report presents quantitative data on another S protein effect: consequences of interactions with host nonantibody proteins. One such interaction, not studied here, is binding to the ACE2 receptor. Measuring the interactions made by the S and E proteins with human proteins may be crucial to understanding COVID-19 and the SARS-CoV-2 variants. We are still in the early stages of understanding SARS-CoV-2 and COVID-19. While our findings may be meaningful and important, they represent only part of the required knowledge about SARS-CoV-2 and COVID-19.

SNG designed and performed the experiments, analyzed the data, and prepared the manuscript. HAL designed the experiments, analyzed the data, prepared the manuscript, and supervised the project. 

The ORF4a protein of human coronavirus 229E functions as a viroporin that regulates viral production

Beyond Channel Activity: Protein-Protein Interactions Involving Viroporins

Viroporins and inflammasomes: A key to understand virus-induced inflammation

Ion-channel activity of influenza-A virus M(2) protein -characterization of the amantadine block

The envelope protein of SARS-CoV-2 increases intra-Golgi pH and forms a cation channel that is regulated by pH

Protein-Protein Interactions of Viroporins in Coronaviruses and Paramyxoviruses: New Targets for Antivirals? Viruses-Basel

A SARS-CoV-2 protein interaction map reveals targets for drug repurposing

Emerging coronaviruses: Genome structure, replication, and pathogenesis

Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Master Regulator Analysis of the SARS-CoV-2/Human interactome

Proliferative growth of SARS coronavirus in Vero E6 cells

SARS-CoV proteins decrease levels and activity of human ENaC via activation of distinct PKC isoforms

Treatment of pulmonary edema by ENaC activators/stimulators

Acral edema during the COVID-19 pandemic

Pulmonary edema in COVID-19: Explained by bradykinin?

Nedd4-2 isoforms ubiquitinate individual epithelial sodium channel subunits and reduce surface expression and function of the epithelial sodium channel

Structural basis of receptor recognition by SARS-CoV-2

Probing Binding Interactions of Cytisine Derivatives to the α4β2 Nicotinic Acetylcholine Receptor

Menthol Stereoisomers Exhibit Different Effects on α4β2 nAChR Upregulation and Dopamine Neuron Spontaneous Firing

A rapid Western blotting protocol for the Xenopus oocyte

Identification of a Golgi Complex-Targeting Signal in the Cytoplasmic Tail of the Severe Acute Respiratory Syndrome Coronavirus Envelope Protein

SARS-CoV-2 infection of primary human lung epithelium for COVID-19 modeling and drug discovery

Tyrosine decaging leads to substantial membrane trafficking during modulation of an inward rectifier potassium channel

Viral and cellular small integral membrane proteins can modify ion channels endogenous to Xenopus oocytes

Role of Severe Acute Respiratory Syndrome Coronavirus Viroporins E, 3a, and 8a in Replication and Pathogenesis

A molecular pore spans the double membrane of the coronavirus replication organelle

Nicotine-Modulated Subunit Stoichiometry Affects Stability and Trafficking of α3β4 Nicotinic Receptor

Preferential assembly of epithelial sodium channel (ENaC) subunits in Xenopus oocytes: role of furin-mediated endogenous proteolysis

SARS-CoV-2 strategically mimics proteolytic activation of human ENaC

A Pathophysiological Model for COVID-19: Critical Importance of Transepithelial Sodium Transport upon

Hypothetical dysfunction of the epithelial sodium channel may justify neurohumoral blockade in coronavirus disease 2019

Regulation of membrane trafficking and endocytosis by protein kinase C: emerging role of the pericentrion, a novel protein kinase C-dependent subset of recycling endosomes

Activation of protein kinase C by phorbol ester induces downregulation of the Na+/K(+)-ATPase in oocytes of Xenopus laevis

Selective inhibition of protein kinase C isozymes by the indolocarbazole Gö 6976

Structural insight into the putative role of novel SARS CoV-2 E protein in viral infection: a potential target for LAV development and therapeutic strategies

In silico identification of Tretinoin as a SARS-CoV-2 envelope (E) protein ion channel inhibitor

Cryo-EM structure of the SARS-CoV-2 3a ion channel in lipid nanodiscs. bioRxiv : the preprint server for biology

The recruitment of membrane-bound mRNAs for translation in microinjected Xenopus oocytes

Structure of the hemagglutinin precursor cleavage site, a determinant of influenza pathogenicity and the origin of the labile conformation

SARS-CoV-2 selectively mimics a cleavable peptide of human ENaC in a strategic hijack of host proteolytic machinery

SARS-CoV-2-specific virulence factors in COVID-19

Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms